SCHEMBL1198167

SCHEMBL1198167

OCc1ncc(-c2ccc(Cl)c(Cl)c2)s1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.41
SLC6A4 P31645 2/20 0.41
SLC6A3 Q01959 2/20 0.41
LOXL2 Q9Y4K0 2/20 0.41
AHR P35869 2/20 0.41
STK17B O94768 1/20 0.40
DHFR P00374 1/20 0.40
SLC5A2 P31639 3/20 0.39
KDM4E B2RXH2 2/20 0.39
MAPT P10636 2/20 0.39
LMNA P02545 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
KMO O15229 3/20 0.38
ALDH1A1 P00352 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ERCC5 P28715 1/20 0.38
FEN1 P39748 1/20 0.38
HRH1 P35367 1/20 0.38
EIF4E P06730 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1198472 0.78 NOTUM (0.51) SLC6A2SLC6A4SLC6A3LOXL2STK17B
SCHEMBL22816215 0.76 AHR (0.46) SLC6A2SLC6A4SLC6A3AHRSTK17B
SCHEMBL22816212 0.75 AHR (0.45) SLC6A2SLC6A4SLC6A3AHRSTK17B
SCHEMBL2404661 0.75 AHR (0.45) SLC6A2SLC6A4SLC6A3AHRDHFR
SCHEMBL2226003 0.74 ERCC5 (0.63) LOXL2SLC5A2ERCC5FEN1
SCHEMBL7483833 0.73 KDR (0.47) AHRKDM4EMAPTLMNARAB9A
SCHEMBL12875717 0.73 HSD17B1 (0.51) LOXL2KDM4EMAPTRAB9AKMT2A
Bromide SCHEMBL7484721 0.72 KDR (0.46) AHRKDM4EMAPTLMNARAB9A
SCHEMBL22042127 0.71 FEN1 (0.43) LOXL2ERCC5FEN1
SCHEMBL1198760 0.71 LOXL2 (0.48) LOXL2MAPTKMT2AALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
EP-2264017-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A SLC6A2 2472/4885SLC6A4 2973/4885SLC6A3 2683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.